Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 12, Issue 2 (Vol.12 No.2 Jul 2023)
rbmb.net 2023, 12(2): 251-258 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohamed Mekawy D, Eissa M, Adly Sadik N, Mohamed Abd-Elrahman R, Fawzy A, Fathy Amer M. Vitamin D and miRNA-155 in Behçet’s Disease: Possible Association with the Disease and Disease Activity. rbmb.net 2023; 12 (2) :251-258
URL: http://rbmb.net/article-1-1170-en.html
URL: http://rbmb.net/article-1-1170-en.html
Dina Mohamed Mekawy 
, Mervat Eissa * , Noha Adly Sadik , Rana Mohamed Abd-Elrahman , Ahmed Fawzy , Marwa Fathy Amer
, Mervat Eissa * , Noha Adly Sadik , Rana Mohamed Abd-Elrahman , Ahmed Fawzy , Marwa Fathy Amer
Rheumatology Department, Faculty of Medicine, Cairo University, Egypt.
Abstract: (1358 Views)
Background: Vitamin D (vit D) controls inflammation and immunity. In Behçet’s disease (BD), microRNA-155 is recognized as a significant immune response regulator. We aimed to investigate the role of vit D on immunomodulation and downregulation of inflammatory pathways associated with BD and detect the role of miRNA-155 in BD.
Methods: miRNA-155 expression by Real Time -Polymerase Chain Reaction (RT-PCR), and vit D, nuclear factor Kappa-light-chain-enhancer of activated B cells (NF-κB), and Tumor necrosis fact of TNF-α) expression by Enzyme Linked Immunosorbent Assay (ELISA) were assessed.
Results: BD patients had a significantly higher relative expression of microRNA-155 (P< 0.001), it was significantly related to vascular manifestations (P< 0.001). Vit D relative expression was significantly low in BD (P< 0.001). There was a significant rise in miRNA-155 in the active group compared to the inactive group (P< 0.001). A significant decrease in vit D levels (IU) was found in inactive and active individuals suffering from BD when compared to controls (P< 0.001). A significant rise was found in vit D levels in inactive BD cases (P< 0.001). A significant positive correlations were found between miRNA-155, NF-κB, TNF-α, and negative correlations with vit D relative expression in BD patients.
Conclusions: miRNA-155 relative expression is higher in BD is significantly related to vascular manifestations. It may have a relationship to disease activity. Vitamin D relative expression is significantly low in BD patients, which can significantly influence immunomodulatory BD therapy. Vitamin D deficiency linked to active BD.
Methods: miRNA-155 expression by Real Time -Polymerase Chain Reaction (RT-PCR), and vit D, nuclear factor Kappa-light-chain-enhancer of activated B cells (NF-κB), and Tumor necrosis fact of TNF-α) expression by Enzyme Linked Immunosorbent Assay (ELISA) were assessed.
Results: BD patients had a significantly higher relative expression of microRNA-155 (P< 0.001), it was significantly related to vascular manifestations (P< 0.001). Vit D relative expression was significantly low in BD (P< 0.001). There was a significant rise in miRNA-155 in the active group compared to the inactive group (P< 0.001). A significant decrease in vit D levels (IU) was found in inactive and active individuals suffering from BD when compared to controls (P< 0.001). A significant rise was found in vit D levels in inactive BD cases (P< 0.001). A significant positive correlations were found between miRNA-155, NF-κB, TNF-α, and negative correlations with vit D relative expression in BD patients.
Conclusions: miRNA-155 relative expression is higher in BD is significantly related to vascular manifestations. It may have a relationship to disease activity. Vitamin D relative expression is significantly low in BD patients, which can significantly influence immunomodulatory BD therapy. Vitamin D deficiency linked to active BD.
Type of Article: Original Article |
Subject:
Immunology
Received: 2023/04/28 | Accepted: 2023/08/18 | Published: 2023/12/20
Received: 2023/04/28 | Accepted: 2023/08/18 | Published: 2023/12/20
attachement [PDF 430 KB] (55 Download)
References
1. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60(11):996-1002. [DOI:10.1136/ard.60.11.996] [PMID] []
2. Karasneh J, Gül A, Ollier WE, Silman AJ, Worthington J. Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. Arthritis Rheum. 2005;52(6):1836-42. [DOI:10.1002/art.21060] [PMID]
3. Hughes T, Ture-Ozdemir F, Alibaz-Oner F, Coit P, Direskeneli H, Sawalha AH. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behçet's disease. Arthritis Rheumatol. 2014;66(6):1648-58. [DOI:10.1002/art.38409] [PMID] []
4. Anetakis C, Mitka S, Chatzidimitriou M, Anagnostopoulos K, Eleftheriou P, Lialiaris T. Vitamin D Status in Osteoporotic and Diabetic Patients and Athletic Healthy Individuals from Northern Greece. Rep Biochem Mol Biol. 2023;11(4):565-576. [DOI:10.52547/rbmb.11.4.565] [PMID] []
5. Zarei M, Javanbakht MH, Jafary H, Djalali M. Evaluation of the Effect of Vitamin D Supplementation on Anthropometric Indicators and Dietary Intake of Patients with Type 2 Diabetes. Rep Biochem Mol Biol. 2021;9(4):490-497. [DOI:10.52547/rbmb.9.4.490] [PMID] []
6. Zhou Q, Hou S, Liang L, Li X, Tan X, Wei L, et al. MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome. Ann Rheum Dis. 2014;73(1):170-6. [DOI:10.1136/annrheumdis-2012-201627] [PMID]
7. Kolahi S, Farajzadeh MJ, Alipour S, Abhari A, Farhadi J, Bahavarnia N, et al. Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-α and CTLA4 genes in patients with Behcet's disease. Immunol Lett. 2018;204:55-59. [DOI:10.1016/j.imlet.2018.10.012] [PMID]
8. Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q, et al. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39(1):67. [DOI:10.1186/s13046-020-01570-6] [PMID] []
9. Zhu JG, Ochalek JT, Kaufmann M, Jones G, Deluca HF. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A. 2013;110(39):15650-5. [DOI:10.1073/pnas.1315006110] [PMID] []
10. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-47. [DOI:10.1111/jdv.12107] [PMID]
11. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet's disease activity index. Rheumatology (Oxford). 2004;43(1):73-8. [DOI:10.1093/rheumatology/keg453] [PMID]
12. Krause I, Mader R, Sulkes J, Paul M, Uziel Y, et al. Behçet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol. 2001;28(5):1033-6.
13. Karatay S, Yildirim K, Karakuzu A, Kiziltunc A, Engin RI, Eren YB, Aktas A. Vitamin D status in patients with Behcet's Disease. Clinics (Sao Paulo). 2011;66(5):721-3.
14. Skrobot A, Demkow U, Wachowska M. Immunomodulatory Role of Vitamin D: A Review. Adv Exp Med Biol. 2018;1108:13-23. [DOI:10.1007/5584_2018_246] [PMID]
15. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36(2):361-70. [DOI:10.1002/eji.200425995] [PMID]
16. Khabbazi A, Rashtchizadeh N, Ghorbanihaghjo A, Hajialiloo M, Ghojazadeh M, Taei R, Kolahi S. The status of serum vitamin D in patients with active Behcet's disease compared with controls. Int J Rheum Dis. 2014;17(4):430-4. [DOI:10.1111/1756-185X.12153] [PMID]
17. Can M, Gunes M, Haliloglu OA, Haklar G, Inanç N, Yavuz DG, Direskeneli H. Effect of vitamin D deficiency and replacement on endothelial functions in Behçet's disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S57-61.
18. Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of Toll- like receptors of monocytes from patients with Behçet's disease. Rheumatology (Oxford); 2008, 47(6):840-8. [DOI:10.1093/rheumatology/ken109] [PMID]
19. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18(18):2195-224. [DOI:10.1101/gad.1228704] [PMID]
20. Baud V, Jacque E. The alternative NF-kB activation pathway and cancer: friend or foe?. Med Sci (Paris). 2008;24(12):1083-8. [DOI:10.1051/medsci/200824121083] [PMID]
21. Ji J, Xu M, Tu J, Zhao Z, Gao J, Chen M, et al. MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of hepatocellular carcinoma. Oncotarget. 2016;7(37):60303-60309. [DOI:10.18632/oncotarget.11206] [PMID] []
22. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-14. [DOI:10.1016/j.cell.2007.04.040] [PMID] []
23. Zeng L, Cui J, Wu H, Lu Q. The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity. 2014;47(7):419-29. [DOI:10.3109/08916934.2014.929667] [PMID]
24. Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia-Flores Y, et al. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017;8(1):851. [DOI:10.1038/s41467-017-00972-z] [PMID] []
25. El Khateeb, E, Nassef, A, Gheith, R, Erfan A, Abdelfattah W. Expression of miR-146a and miR-155 in Egyptian patients with Behçet's disease: clinical significance and relationship with disease activity. Egypt J Med Hum Genet. 2020; 21(43). [DOI:10.1186/s43042-020-00085-1]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
